Plain-English translation of NCT06510374 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called for people who have been diagnosed with intermediate-risk non-muscle invasive bladder cancer (cancer that hasn't grown into the deepest muscle layer of the bladder). Half of participants will receive quarterly treatments with this medication over 2 years, while the other half will follow standard monitoring visits to watch for any changes.
After surgery to remove bladder tumors, cancer often comes back even in people with intermediate-risk disease. This trial is exploring whether this medication can help prevent recurrence and improve long-term outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to one of two groups. One group will receive the medication as a quarterly bladder instillation (a treatment delivered directly into the bladder) for 2 years, with disease check-up visits before each treatment. The other group will follow standard follow-up visits every 3 months for 2 years without the medication. Both groups will be closely monitored to see how well the treatment works and ensure your safety.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
United States